U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CVM GFI #205 (VICH GL46) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Metabolism Study to Determine the Quantity and Identify the Nature of Residues (MRK)
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

CVM GFI #205 (VICH GL46) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Metabolism Study to Determine the Quantity and Identify the Nature of Residues (MRK) September 2011

Final
Docket Number:
FDA-2010-D-8228
Issued by:
Guidance Issuing Office
Center for Veterinary Medicine

The human food safety evaluation of veterinary drug residues helps ensure that food derived from treated food-producing animals is safe for human consumption. As part of the data collection process, studies should be conducted to permit an assessment of the quantity and nature of residues in food derived from animals treated with a veterinary drug. These metabolism studies provide data on (1) the depletion of residues of concern from edible tissues of treated animals at varying times after drug administration, (2) the individual components, or residues, that comprise the residue of concern in edible tissues, (3) the residue(s) that can serve as a marker for analytical methods intended for compliance purposes (i.e., monitoring of appropriate drug use), and (4) the identification of a target tissue or tissues, as applicable to national or regional programs.

Metabolism studies in food-producing animals most often are accomplished using radiolabeled drugs. These studies are sometimes referred to as total residue studies because they are capable of monitoring all (i.e., “total”) drug-derived residues resulting from the administration of test material. This guidance recommends procedures for metabolism studies conducted with radiolabeled drugs, when such studies are performed.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2010-D-8228.

Questions?

Back to Top